{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:04:20Z","timestamp":1773885860048,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00432-020-03192-z","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T12:02:58Z","timestamp":1585310578000},"page":"1867-1876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data"],"prefix":"10.1007","volume":"146","author":[{"given":"Huijuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeming","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"issue":"11","key":"3192_CR1","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.5858\/arpa.2013-0388-OA","volume":"138","author":"G Al\u00ec","year":"2014","unstructured":"Al\u00ec G, Proietti A, Pelliccioni S et al (2014) ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med 138(11):1449\u20131458","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"3192_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"7511","key":"3192_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543\u2013550","journal-title":"Nature"},{"issue":"3","key":"3192_CR4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs CC, Zehir A, Devlin SM et al (2017) Therapy-related clonal therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21(3):374\u2013382.e4","journal-title":"Cell Stem Cell"},{"issue":"6892","key":"3192_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954","journal-title":"Nature"},{"issue":"8","key":"3192_CR6","doi-asserted-by":"publisher","first-page":"13611","DOI":"10.18632\/oncotarget.6957","volume":"8","author":"M Del Re","year":"2017","unstructured":"Del Re M, Tiseo M, Bordi P et al (2017) Contribution of KRAS mutations and c.2369 C%3eT(p.T790M)EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget 8(8):13611\u201313619","journal-title":"Oncotarget"},{"issue":"4","key":"3192_CR7","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.21037\/jtd.2019.03.95","volume":"11","author":"MG Denis","year":"2019","unstructured":"Denis MG, Lafourcade MP, Le Garff G et al (2019) Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. J Thorac Dis 11(4):1370\u20131378","journal-title":"J Thorac Dis"},{"issue":"16","key":"3192_CR8","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-14-2683","volume":"21","author":"A Drilon","year":"2015","unstructured":"Drilon A, Wang L, Arcila ME et al (2015) Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 21(16):3631\u20133639","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3192_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2015.0071","volume":"13","author":"DS Ettinger","year":"2015","unstructured":"Ettinger DS, Wood DE, Akerley W et al (2015) Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw 13(5):515\u2013524","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"3192_CR10","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1021\/jm500973a","volume":"57","author":"MR Finlay","year":"2014","unstructured":"Finlay MR, Anderton M, Ashton S et al (2014) Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 57(20):8249\u20138267","journal-title":"J Med Chem"},{"issue":"31","key":"3192_CR11","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","volume":"31","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Shaw AT (2013) Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31(31):3987\u20133996","journal-title":"J Clin Oncol"},{"issue":"10","key":"3192_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883\u2013892","journal-title":"N Engl J Med"},{"issue":"5","key":"3192_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1470-2045(09)70110-X","volume":"10","author":"FR Hirsch","year":"2009","unstructured":"Hirsch FR, Bunn PA Jr (2009) EGFR testing in lung cancer is ready for prime time. Lancet Oncol 10(5):432\u2013433","journal-title":"Lancet Oncol"},{"issue":"26","key":"3192_CR14","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488\u20132498","journal-title":"N Engl J Med"},{"key":"3192_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3389\/fgene.2019.00470.eCollection","volume":"10","author":"N Jia","year":"2019","unstructured":"Jia N, Sun Z, Gao X, Cheng Y et al (2019) Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response. Front Genet 10:470. https:\/\/doi.org\/10.3389\/fgene.2019.00470.eCollection","journal-title":"Front Genet"},{"issue":"37","key":"3192_CR16","doi-asserted-by":"publisher","first-page":"E5528","DOI":"10.1073\/pnas.1522203113","volume":"113","author":"QY JiangY","year":"2016","unstructured":"JiangY QY, Minn AJ, Zhang NR (2016) Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proc Natl Acad Sci USA 113(37):E5528\u2013E5537","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"3192_CR17","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","volume":"20","author":"R Katayama","year":"2014","unstructured":"Katayama R, Friboulet L, Koike S et al (2014) Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib. Clin Cancer Res 20(22):5686\u20135696","journal-title":"Clin Cancer Res"},{"key":"3192_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00158","author":"S Kato","year":"2019","unstructured":"Kato S, Schwaederl\u00e9 MC, Fanta PT et al (2019) Genomic assessment of blood-derived circulating tumor DNA in patients with colorectal cancers: correlation with tissue sequencing, therapeutic response, and survival. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00158","journal-title":"JCO Precis Oncol"},{"key":"3192_CR19","doi-asserted-by":"publisher","first-page":"165214","DOI":"10.1155\/2011\/165214","volume":"2011","author":"T Kosaka","year":"2011","unstructured":"Kosaka T, Yamaki E, Mogi A, Kuwano H (2011) Mechanisms of resistance to EGFR TKIs and development of a new generations of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011:165214. https:\/\/doi.org\/10.1155\/2011\/165214","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"3192_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.molonc.2014.12.003","volume":"9","author":"R Lebofsky","year":"2015","unstructured":"Lebofsky R, Decraene C, Bernard V et al (2015) Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumorgenotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9(4):783\u2013790","journal-title":"Mol Oncol"},{"issue":"2","key":"3192_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1046\/j.1537-2995.2001.41020276.x","volume":"41","author":"TH Lee","year":"2001","unstructured":"Lee TH, Montalvo L, Chrebtow V, Busch MP (2001) Quantitation of genomic DNA in plasma and serum samples:higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41(2):276\u2013282","journal-title":"Transfusion"},{"issue":"11","key":"3192_CR22","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1038\/bjc.2014.210","volume":"110","author":"S Li","year":"2014","unstructured":"Li S, Li L, Zhu Y, Huang C et al (2014) Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer 110(11):2812\u20132820","journal-title":"Br J Cancer"},{"issue":"11","key":"3192_CR23","doi-asserted-by":"publisher","first-page":"e0166354","DOI":"10.1371\/journal.pone.0166354","volume":"11","author":"I Medina Diaz","year":"2016","unstructured":"Medina Diaz I, Nocon A, Mehert DH, Fredebohm J, Diehl F, Holtrup F (2016) Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS ONE 11(11):e0166354","journal-title":"PLoS ONE"},{"key":"3192_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2017.11.011","volume":"115","author":"R Minari","year":"2018","unstructured":"Minari R, Bordi P, Del Re M et al (2018) Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer 115:21\u201327","journal-title":"Lung Cancer"},{"issue":"4","key":"3192_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3816\/CLC.2009.n.039","volume":"10","author":"KS Nguyen","year":"2009","unstructured":"Nguyen KS, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281\u2013289","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"3192_CR26","doi-asserted-by":"publisher","first-page":"12501","DOI":"10.18632\/oncotarget.13915","volume":"8","author":"N Normanno","year":"2017","unstructured":"Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M (2017) Guide to detecting epidermal growth factor receptor(EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget 8(7):12501\u201312516","journal-title":"Oncotarget"},{"issue":"31","key":"3192_CR27","doi-asserted-by":"publisher","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","volume":"109","author":"K Ohashi","year":"2012","unstructured":"Ohashi K, Sequist LV, Arcila ME et al (2012) Lung cancers with acquired resistance to EGFR resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 109(31):E2127\u2013E2133","journal-title":"Proc Natl Acad Sci USA"},{"key":"3192_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1196\/annals.1368.042","volume":"1075","author":"K Page","year":"2006","unstructured":"Page K, Powles T, Slade MJ, De Bella MT, Walker RA, Coombes RC, Shaw JA (2006) The importance of careful blood processing in isolation of cell-free DNA. Ann NY Acad Sci 1075:313\u2013317","journal-title":"Ann NY Acad Sci"},{"issue":"7","key":"3192_CR29","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.jtho.2017.02.023","volume":"12","author":"N Peled","year":"2017","unstructured":"Peled N, Roisman LC, Miron B et al (2017) Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer. J Thorac Oncol 12(7):e81\u2013e84","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3192_CR30","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAF( V600E) mutant metastatic non-small cell lung cancer: an open label, multicenter phase 2 trial. Lancet Oncol 17(7):984\u2013993","journal-title":"Lancet Oncol"},{"issue":"10","key":"3192_CR31","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM et al (2017) Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 18(10):1307\u20131316","journal-title":"Lancet Oncol"},{"issue":"3","key":"3192_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/15384047.2016.1139238","volume":"17","author":"D Que","year":"2016","unstructured":"Que D, Xiao H, Zhao B et al (2016) EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer Biol Ther 17(3):320\u2013327","journal-title":"Cancer Biol Ther"},{"issue":"6901","key":"3192_CR33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/418934a","volume":"418","author":"H Rajagopalan","year":"2002","unstructured":"Rajagopalan H, Bardelli A, Lengauer C et al (2002) Tumorigenesis:RAF\/RAS oncogenes and mismatch -repair status. Nature 418(6901):934","journal-title":"Nature"},{"issue":"9","key":"3192_CR34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","volume":"13","author":"C Rolfo","year":"2018","unstructured":"Rolfo C, Mack PC, Scagliotti GV et al (2018) Liquid biopsy for advanced non-small cell lung cancer( NSCLC): a statement paper from the IASLC. J Thorac Oncol 13(9):1248\u20131268","journal-title":"J Thorac Oncol"},{"issue":"10","key":"3192_CR35","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958\u2013967","journal-title":"N Engl J Med"},{"issue":"5","key":"3192_CR36","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","volume":"17","author":"R Rosell","year":"2011","unstructured":"Rosell R, Molina MA, Costa C et al (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17(5):1160\u20131168","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3192_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jtho.2018.10.008","volume":"14","author":"AB Schrock","year":"2019","unstructured":"Schrock AB, Welsh A, Chung JH et al (2019) Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced Non-Small Cell Lung Cancer. J Thorac Oncol 14(2):255\u2013264","journal-title":"J Thorac Oncol"},{"issue":"17","key":"3192_CR38","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-16-2497","volume":"23","author":"MC Schwaederl\u00e9","year":"2017","unstructured":"Schwaederl\u00e9 MC, Patel SP, Husain H et al (2017) Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res 23(17):5101\u20135111","journal-title":"Clin Cancer Res"},{"issue":"17","key":"3192_CR39","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/JCO.2012.48.1390","volume":"31","author":"FA Shepherd","year":"2013","unstructured":"Shepherd FA, Domerg C, Hainaut P et al (2013) Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small- cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 31(17):2173\u20132181","journal-title":"J Clin Oncol"},{"issue":"2","key":"3192_CR40","doi-asserted-by":"publisher","first-page":"e0150197","DOI":"10.1371\/journal.pone.0150197","volume":"11","author":"JL Sherwood","year":"2016","unstructured":"Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M, Kohlmann A (2016) Optimised pre-ana lytica methods improve KRAS mutation detection in circulating TumourDNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS ONE 11(2):e0150197","journal-title":"PLoS ONE"},{"issue":"5","key":"3192_CR41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","volume":"10","author":"LM Sholl","year":"2015","unstructured":"Sholl LM, Aisner DL, Varella-Garcia M et al (2015) Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol 10(5):768\u2013777","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3192_CR42","doi-asserted-by":"publisher","first-page":"E290","DOI":"10.3390\/cancers10090290","volume":"10","author":"L Sorber","year":"2018","unstructured":"Sorber L, Zwaenepoel K, De Winne K, Van Casteren K et al (2018) A multicenter study to assess EGFR mutational status in plasma: focus on an optimized workflow for liquid biopsy in a clinical setting. Cancers (Basel) 10(9):E290","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3192_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/cas.12847","volume":"107","author":"N Sueoka-Aragane","year":"2016","unstructured":"Sueoka-Aragane N, Katakami N, Satouchi M et al (2016) Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci 107(2):162\u2013167","journal-title":"Cancer Sci"},{"issue":"23","key":"3192_CR44","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","volume":"22","author":"JC Thompson","year":"2016","unstructured":"Thompson JC, Yee SS, Troxel AB et al (2016) Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22(23):5772\u20135782","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3192_CR45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.1167.11.3","volume":"11","author":"M Tokumo","year":"2005","unstructured":"Tokumo M, Toyooka S, Kiura K et al (2005) The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11(3):1167\u20131173","journal-title":"Clin Cancer Res"},{"key":"3192_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00227","author":"S Torquato","year":"2019","unstructured":"Torquato S, Pallavajjala A, Goldstein A et al (2019) Genetic alterations detected in cell- free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00227","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"3192_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.lungcan.2013.11.023","volume":"83","author":"B Weber","year":"2014","unstructured":"Weber B, Hager H, Sorensen BS et al (2014) EGFR mutation frequency and effectiveness of erlotinib:a prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer 83(2):224\u2013230","journal-title":"Lung Cancer"},{"issue":"27","key":"3192_CR48","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","volume":"31","author":"JC Yang","year":"2013","unstructured":"Yang JC, Hirsh V, Schuler M et al (2013) Symptom control and quality of life in LUX-lung 3: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutation. J Clin Oncol 31(27):3342\u20133350","journal-title":"J Clin Oncol"},{"issue":"10","key":"3192_CR49","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/cncy.21743","volume":"124","author":"G Zheng","year":"2016","unstructured":"Zheng G, Lin MT, Lokhandwala PM et al (2016) Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next generation sequencing. Cancer Cytopathol 124(10):744\u2013753","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"3192_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/annonc\/mdy512","volume":"30","author":"J Zugazagoitia","year":"2019","unstructured":"Zugazagoitia J, Ramos I, Trigo JM et al (2019) Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol 30(2):290\u2013296","journal-title":"Ann Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03192-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03192-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03192-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T21:20:51Z","timestamp":1666214451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03192-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["3192"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03192-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,27]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}